Metraipolis › archive › dc_adbc16d6bbc6

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives — Europe PMC PMID:41550808

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41550808
DOI
10.1039/d5ra09034b
License (as archived)
solo-consultazione
Archived
2026-11-06T18:51:17.729Z
SHA-256 of the archived text
be940c21e3fa21eee8608597adc88e5079b037845534e9e430eeda32c7194118
Stable URL of this page
https://metraipolis.com/documento/dc_adbc16d6bbc6

How to cite

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives — Europe PMC PMID:41550808 — Europe PMC (en), https://europepmc.org/article/MED/41550808 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_adbc16d6bbc6 (Metraipolis archive dc_adbc16d6bbc6, sha256 be940c21e3fa21eee8608597adc88e5079b037845534e9e430eeda32c7194118)
BibTeX
@misc{dcadbc16d6bbc6,
  title = {HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives — Europe PMC PMID:41550808},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41550808},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_adbc16d6bbc6; sha256 be940c21e3fa21eee8608597adc88e5079b037845534e9e430eeda32c7194118},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41550808. Agents can read the archived copy with the MCP tool read_document.